RecruitingPhase 2NCT06807606

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

Studying Hinman syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Warren Fingrut, MD, MD
M.D. Anderson Cancer Center
Intervention
Drugs Cyclophosphamide(drug)
Enrollment
35 target
Eligibility
60 years · All sexes
Timeline
20252029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06807606 on ClinicalTrials.gov

Other trials for Hinman syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hinman syndrome

← Back to all trials